Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Help With PCOS (PMOS)? What Studies Found

GLP-1 medicines may help with weight loss in PCOS. Evidence for menstrual, metabolic and fertility outcomes is more limited.

Editorial profile: Carla MedinaBuy This GLP Editorial Team5 min read

A May 2026 international consensus adopted the name polyendocrine metabolic ovarian syndrome (PMOS). Many of the studies discussed here use the previous name, polycystic ovary syndrome (PCOS) [1]. Our review of GLP-1 prescribing records includes prescriptions after a PCOS diagnosis. Prescription records and randomized trials answer different questions.

What randomized studies found

A systematic review of 11 randomized trials found BMI was 1.38 kg/m² lower (95% CI: 0.38 to 2.39 kg/m² lower) with GLP-1 receptor agonists as an add-on treatment, compared with control groups. The authors rated the evidence as low certainty and found too little evidence to draw conclusions about glucose, insulin, excessive hair growth or menstrual regularity [2].

The comparison with metformin describes the outcomes measured in studies of the two treatments. Check which outcome a study measured before using it to compare treatment options.

In a small open-label randomized trial (n = 64) of women with PCOS-related infertility and overweight or obesity, adding semaglutide to metformin improved menstrual regularity during short follow-up compared with metformin alone [3]. That finding cannot establish a benefit for pregnancy or live birth. The international guideline supports considering anti-obesity medication for higher weight according to general-population guidance and recommends using it for reproductive outcomes only in research settings [4].

What the tirzepatide cohort can tell us

Researchers studying tirzepatide in a UK online weight-management program reported similar weight-loss trajectories in women with and without self-reported PCOS. Everyone in the comparison received tirzepatide. PCOS status and weight were self-reported, and the study did not measure whether menstrual cycles, androgen symptoms or fertility improved [5].

What prescribing records and program fees tell you

In one Polish private health network, the proportion starting an incretin-based medicine within a year of PCOS diagnosis rose from 0.14% in 2018 to 5.97% in 2024. Among incretin users, 11.5% had a coded type 2 diabetes diagnosis. That code alone does not establish the reason for a prescription [6].

If you are comparing PCOS Sisters’ GLP-1 management program with another form of care, its advertised starting price is $150 per month and membership is required. Ask which membership and pharmacy charges apply to your prescription [7]. If using insurance, the GLP-1 insurance coverage guide explains how a plan can set different rules by product and indication.

Frequently asked

Are GLP-1 medicines approved to treat PCOS?
PCOS (PMOS) itself is not a U.S. approved indication for these drugs. Some medicines can be prescribed for an approved indication such as chronic weight management or type 2 diabetes when a person meets the relevant criteria.
Can a GLP-1 improve menstrual cycles or fertility in PCOS?
A small trial found more regular cycles when semaglutide was added to metformin. Evidence for fertility outcomes remains uncertain, and the international guideline limits use of anti-obesity medicines for reproductive outcomes to research settings.
Does tirzepatide help with weight loss in people with PCOS?
Women with and without self-reported PCOS had similar recorded weight-loss trajectories in one UK program. The study followed people already taking tirzepatide and did not establish equal effects or improvement in reproductive symptoms.

Sources

  1. [1] Teede HJ, et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process The Lancet. PMID 42119588
  2. [2] Forslund M, et al. (2026). GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis European Journal of Endocrinology. PMID 41701618
  3. [3] Zhang W, Xue J, Wang A (2026). Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial Metabolism and Target Organ Damage. Source
  4. [4] International Evidence-Based Guideline development group (2023). International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (2026 terminology update) Monash University. Source
  5. [5] Clift AK, et al. (2026). Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome Journal of the Endocrine Society. PMID 42634795
  6. [6] Dziewierz A, et al. (2026). Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network Diabetes, Obesity and Metabolism. PMID 42297761
  7. [7] PCOS Sisters (2026). GLP-1 Weight Loss and Metabolic Management PCOS Sisters. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence